Showing results (291-300 of 368) with videos related to

Sort By:
Pageof 37
European Journal of Heart Failure|May 22, 2023
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trialsAnkeet S Bhatt, Mikhail N Kosiborod, Muthiah Vaduganathan, et al.
JAMA Cardiology|March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionKirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
JACC. Heart Failure|September 28, 2023
Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER TrialAlexander Peikert, Bradley A Bart, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|September 2, 2022
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|April 20, 2022
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HFCarly Adamson, Kieran F Docherty, Hiddo J L Heerspink, et al.
JAMA Cardiology|February 22, 2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVERJawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
JACC. Asia|February 19, 2024
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER TrialXiaowen Wang, Carolyn S P Lam, Muthiah Vaduganathan, et al.
JACC. Heart Failure|March 6, 2025
Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVERRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
European Journal of Heart Failure|June 16, 2020
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HFPooja Dewan, Scott D Solomon, Pardeep S Jhund, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
Pageof 37